Cancer cells of ribociclib-sensitive shrinking tumors also provided greater amounts of immune-activating communications to myeloid cells, including stimulation of CCR5/7 receptors43 (e.g., CCL5-CCR5:est = 2.84, df = 6, t = 4.73, p < 0.005) (Supplementary Data 2). This evidence concerns the gene CCL5 and cancer.